Psychosis Clinical Trial
Official title:
An Explorative Experimental Study to Assess the Feasibility, Acceptability and Effectiveness of Imagery Intervention Techniques in the Treatment of Auditory Vocal Hallucinations
Verified date | February 2024 |
Source | Geestelijke Gezondheidszorg Eindhoven (GGzE) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study explores the feasibility, acceptability, and effectiveness of four imagery intervention techniques (metacognitive imagery intervention, imagery rescripting, promoting positive imagery and competing imagery task) for auditory vocal hallucinations using four single case series with an A-B-A within subject design.
Status | Completed |
Enrollment | 32 |
Est. completion date | February 10, 2024 |
Est. primary completion date | February 10, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age 16-65 - Experiencing subclinical or clinical psychotic auditory vocal hallucinations as confirmed by a clinician and as indicated by an intensity score of 4 or more on subscale 1.3 (perceptual abnormalities) of the Comprehensive Assessment of At Risk Mental States (CAARMS) or as indicated by a score of 3 or more on item P3 (hallucinatory behavior) of the Positive and Negative Syndrome Scale (PANSS). - A Diagnostic and Statistical Manual-5 (DSM-5; American Psychiatric Association, 2013) diagnosis in the psychosis spectrum (codes: DSM-5 codes: 297.1; 298.8; 295.40; 295.90; 295.70; 298.8; 298.9) or defined as Ultra High Risk/At Risk Mental State (ARMS or UHR) according to the CAARMS estimated by a clinician. - Willing to complete daily monitoring throughout the duration of the study. - Willing to be assigned to a specific imagery intervention. - Able to attend 3 consecutive weekly session of imagery intervention and during this period 3 online check-ups. - Able and willing to sign informed consent Exclusion Criteria: - Any current or previous neurological disorder or organic brain disease. - Acute confusional state or delirium not caused by the psychotic disorder. - Unwillingness to participate - Intelligence quotient (IQ) < 70 estimated by clinician. - Current severe substance or alcohol misuse impacting treatment (clinicians assessment). |
Country | Name | City | State |
---|---|---|---|
Netherlands | Geestelijke Gezondheidszorg Eindhoven (GGzE) | Eindhoven | Noord-Brabant |
Lead Sponsor | Collaborator |
---|---|
Hella Janssen |
Netherlands,
Hales SA, Di Simplicio M, Iyadurai L, Blackwell SE, Young K, Fairburn CG, Geddes JR, Goodwin GM, Holmes EA. Imagery-Focused Cognitive Therapy (ImCT) for Mood Instability and Anxiety in a Small Sample of Patients with Bipolar Disorder: a Pilot Clinical Audit. Behav Cogn Psychother. 2018 Nov;46(6):706-725. doi: 10.1017/S1352465818000334. Epub 2018 Jul 9. — View Citation
Ison R, Medoro L, Keen N, Kuipers E. The use of rescripting imagery for people with psychosis who hear voices. Behav Cogn Psychother. 2014 Mar;42(2):129-42. doi: 10.1017/S135246581300057X. Epub 2013 Aug 7. — View Citation
Paulik G, Steel C, Arntz A. Imagery rescripting for the treatment of trauma in voice hearers: a case series. Behav Cogn Psychother. 2019 Nov;47(6):709-725. doi: 10.1017/S1352465819000237. Epub 2019 Apr 12. — View Citation
Taylor CDJ, Bee PE, Kelly J, Emsley R, Haddock G. iMAgery focused psychological therapy for persecutory delusions in PSychosis (iMAPS): a multiple baseline experimental case series. Behav Cogn Psychother. 2020 Sep;48(5):530-545. doi: 10.1017/S1352465820000168. Epub 2020 Apr 8. — View Citation
van den Berg KC, Hendrickson AT, Hales SA, Voncken M, Keijsers GPJ. Comparing the effectiveness of imagery focussed cognitive therapy to group psychoeducation for patients with bipolar disorder: A randomised trial. J Affect Disord. 2023 Jan 1;320:691-700. doi: 10.1016/j.jad.2022.09.160. Epub 2022 Oct 5. — View Citation
van den Berg KC, Voncken M, Hendrickson AT, Houterman S, Keijsers GPJ. Image qualities and mood variability: Evaluating the utility of an imagery survey for bipolar disorder. J Affect Disord. 2020 Jul 1;272:77-83. doi: 10.1016/j.jad.2020.03.098. Epub 2020 Apr 29. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mediation variable: Change from baseline level of anxiety to follow-up at two weeks after end of therapy. | Measured daily with a visual analogue scale (ranging from 0-100, lower score indicates a better outcome) three times a day with the diary item of anxiety. | Measured three times a day during two weeks of baseline, three weeks of intervention and two weeks of follow-up (an average of 7 weeks) | |
Other | Mediation variable: Change from baseline level of depression to follow-up at two weeks after end of therapy. | Measured daily with a visual analogue scale (ranging from 0-100, lower score indicates a better outcome) three times a day with the diary item of depression. | Measured three times a day during two weeks of baseline, three weeks of intervention and two weeks of follow-up (an average of 7 weeks) | |
Other | Mediation variable: Change from baseline level of anxiety to follow-up at the end of intervention. | Measured with Beck Anxiety Inventory (BAI). The BAI is a 21-item self-report questionnaire with good psychometric properties used for measuring the severity of anxiety. Answers are rated on a 4-point Likert scale. | Administered before baseline period of two weeks, immediately after two weeks of baseline, and immediately after the end of intervention of three weeks | |
Other | Mediation variable: Change from baseline level of depression to follow-up at the end of intervention. | Measured with the Beck Depression Inventory-II (BDI-II). The BDI-II is widely used self-report questionnaire to assess symptoms of depression and the level of depression. The BDI-II consists of 21 items. Good reliability and validity of the BDI-II have been supported by different studies. | Administered before baseline period of two weeks, immediately after two weeks of baseline, and immediately after the end of intervention of three weeks | |
Primary | Change from baseline level of auditory vocal hallucinations to follow-up at two weeks after end of therapy. | Participants received a text message on their mobile phone with a link to a questionnaire. Participants were asked to fill out the questionnaire immediately after the alert, or, if impossible, the same day. All questions will be preceded with the following sentence: "since the last questionnaire….". The questions about auditory vocal hallucinations are adapted from the auditory vocal hallucination rating scale (AVHRS-Q) | Measured three times a day during two weeks of baseline, three weeks of intervention and two weeks of follow-up (an average of 7 weeks) | |
Primary | Change from baseline level of mental imagery characteristics (frequency of imagery, quality of imagery and appraisals of imagery) to follow-up at two weeks after end of therapy. | Participants received a text message on their mobile phone with a link to a questionnaire. Participants were asked to fill out the questionnaire immediately after the alert, or, if impossible, the same day. All questions will be preceded with the following sentence: "since the last questionnaire….". The questions about mental imagery are adapted from the the Dutch Imagery Survey (DimS) | Measured three times a day during two weeks of baseline, three weeks of intervention and two weeks of follow-up (an average of 7 weeks) | |
Primary | Treatment safety (change from baseline level of auditory verbal hallucinations to follow-up at the end of therapy). | The investigators consider treatment to be unsafe if the severity of AVHs of more than 50% of the patients is exacerbated. This will be determined on a case-by-case basis. Worsening of the severity of auditory vocal hallucinations is determined by an increase of 25% as measured with the self-report version of the auditory vocal hallucination rating scale (AVHRS-Q). | Administered before baseline period of two weeks, immediately after two weeks of baseline, weekly during the intervention of three weeks and immediately after the end of intervention of three weeks | |
Primary | Number of Participants with serious adverse events | The investigators report the total number of (serious) adverse events | Administered through study completion, an average of 7 weeks. | |
Primary | Drop-out rate (i.e., number of participants that drop out) | The investigators report drop-outs. | Administered through study completion, an average of 7 weeks. | |
Primary | Treatment quality | A retrospective self-report assessment is used to evaluate treatment quality. This assessment is based on the retrospective self-report assessment used in a study of one of the co-investigators to evaluate quality of imagery cognitive therapy for bipolar disorders. This is a 32-item self-report questionnaire. Answers are rated on a 5-point Likert scale (ranging from 1 to 5, higher scores indicates a better outcome). | Administered immediately after the end of intervention of three weeks | |
Secondary | Change in level of social and occupational function from baseline to follow-up at the end of intervention. | measured with the Social and Occupational Functioning Scale (SOFAS). The SOFAS is used to assess overall functioning in a single score. This scale ranges from 0 to 100 (higher score indicates a better outcome), is a modified version of the Global Assessment of Functioning (GAF) scale, separating the measures of social and occupations function from the measure of symptoms, and psychological functioning. | Administered before baseline period of two weeks, immediately after two weeks of baseline, and immediately after the end of intervention of three weeks | |
Secondary | The change from baseline (daily) level of delusional/paranoid ideas to follow-up at two weeks after end of therapy. | This is measured with a visual analogue scale (ranging from 0-100, lower score indicates a better outcome) three times a day with the diary item of delusions. | Measured three times a day during two weeks of baseline, three weeks of intervention and two weeks of follow-up (an average of 7 weeks) | |
Secondary | Change from baseline (daily) level of visual hallucinations to follow-up at two weeks after end of therapy. | This is measured with a visual analogue scale (ranging from 0-100, lower score indicates a better outcome) three times a day with the diary item of visual hallucinations. | Measured three times a day during two weeks of baseline, three weeks of intervention and two weeks of follow-up (an average of 7 weeks) | |
Secondary | Change from baseline imagery characteristics to follow-up at the end of therapy. | Measured with the Dutch Imagery Survey (DimS). The DimS starts with an elaborate definition of imagery. Thereafter, participants are asked to recall and describe an example of an image that is typical of the imagery they have experienced over the previous two weeks. Since studies on imagery and psychoses showed that patients with psychosis experience imagery in relation to their psychotic symptoms, the investigators ask participants to recall the imagery they have experienced in conjunction to their voices in the last two weeks. Participants are instructed to recall this image and keep this image in mind while answering the subsequent questions regarding imagery. All items of the DimS are rated on a 9-point Likert scale (ranging from 1-9). The internal consistency of all subscales of the DiMS are good (Cronbachs alpha ranging from 0.71 to 0.87), consistency over time is also good. | Administered before baseline period of two weeks, immediately after two weeks of baseline, and immediately after the end of intervention of three weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04929938 -
Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients
|
N/A | |
Recruiting |
NCT05863572 -
Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda
|
N/A | |
Completed |
NCT04277585 -
Improving Access to Early Psychosis Coordinated Specialty Care
|
N/A | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Not yet recruiting |
NCT05558332 -
Youth Nominated Support Team
|
N/A | |
Not yet recruiting |
NCT05358457 -
Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf)
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Completed |
NCT02895269 -
COllaborative Shared Care to IMprove Psychosis Outcome
|
N/A | |
Recruiting |
NCT02622048 -
Understanding and Helping Families: Parents With Psychosis
|
N/A | |
Completed |
NCT02531243 -
Computer-Aided Learning for Managing Stress
|
N/A | |
Completed |
NCT02653729 -
Cbt for Psychosis and Affect on Psychosis Symptoms
|
Phase 2 | |
Completed |
NCT02733575 -
Compassion Focused Therapy for Distressing Experiences
|
N/A | |
Not yet recruiting |
NCT02244970 -
Mindfulness RCT for Early Psychosis
|
N/A | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Withdrawn |
NCT00786318 -
Ziprasidone vs Standard Therapy for Agitated Patients in the ED
|
Phase 4 | |
Recruiting |
NCT00722163 -
A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis
|
Phase 0 |